ATE349466T1 - Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren - Google Patents

Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren

Info

Publication number
ATE349466T1
ATE349466T1 AT02760073T AT02760073T ATE349466T1 AT E349466 T1 ATE349466 T1 AT E349466T1 AT 02760073 T AT02760073 T AT 02760073T AT 02760073 T AT02760073 T AT 02760073T AT E349466 T1 ATE349466 T1 AT E349466T1
Authority
AT
Austria
Prior art keywords
chimeric
serotype
nucleic acids
acids encoding
obtaining
Prior art date
Application number
AT02760073T
Other languages
English (en)
Inventor
Cruz Lisset Hermida
Diaz Rayner Rodriguez
Vazquez Laura Lazo
Morales Aida Zulueta
Abarrategui Carlos Lopez
Prado Iris Valdes
Rodriguez Ricardo De La Silva
Playa B
Santiago Glay Chinea
Nieto Gerardo Enrique Guillen
Revolucion
Tirado Maria Guadalupe Guzman
Vazquez Beatriz De La C Sierra
Perez Raul Rafael Espinosa
Original Assignee
Ct Ingenieria Genetica Biotech
Inst De Medicina Tropical Pedr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Inst De Medicina Tropical Pedr filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE349466T1 publication Critical patent/ATE349466T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AT02760073T 2001-07-16 2002-07-12 Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren ATE349466T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010172A CU23245A1 (es) 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS

Publications (1)

Publication Number Publication Date
ATE349466T1 true ATE349466T1 (de) 2007-01-15

Family

ID=40091633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760073T ATE349466T1 (de) 2001-07-16 2002-07-12 Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren

Country Status (18)

Country Link
US (4) US7279164B2 (de)
EP (1) EP1418180B1 (de)
JP (1) JP4417712B2 (de)
KR (1) KR100991717B1 (de)
CN (1) CN100378123C (de)
AT (1) ATE349466T1 (de)
BR (1) BR0211178A (de)
CA (1) CA2453300C (de)
CU (1) CU23245A1 (de)
DE (1) DE60217129T2 (de)
DK (1) DK1418180T3 (de)
ES (1) ES2278041T3 (de)
GT (1) GT200200150A (de)
MX (1) MXPA04000486A (de)
MY (1) MY138482A (de)
PT (1) PT1418180E (de)
WO (1) WO2003008571A2 (de)
ZA (1) ZA200400289B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
EP2632485A4 (de) * 2010-10-29 2014-05-28 Merck Sharp & Dohme Dengue-virus-impfstoff mit einer rekombinanten untereinheit
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
ITRM20130458A1 (it) * 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
CN113429479B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2004052293A2 (en) 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (de) 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infektiöse Flavivirus Pseudo-Partikel, welche funktionelle prM-E Hüllproteine enthalten
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
US8105606B2 (en) 2012-01-31
US7566457B2 (en) 2009-07-28
US20070141081A1 (en) 2007-06-21
PT1418180E (pt) 2007-04-30
US20110200628A1 (en) 2011-08-18
ZA200400289B (en) 2004-09-12
EP1418180B1 (de) 2006-12-27
ES2278041T3 (es) 2007-08-01
US20040234951A1 (en) 2004-11-25
KR100991717B1 (ko) 2010-11-03
US7279164B2 (en) 2007-10-09
CU23245A1 (es) 2007-10-17
US20090274718A1 (en) 2009-11-05
DE60217129D1 (de) 2007-02-08
CA2453300C (en) 2012-03-20
MY138482A (en) 2009-06-30
CN1531548A (zh) 2004-09-22
JP2004537306A (ja) 2004-12-16
GT200200150A (es) 2003-06-19
EP1418180A2 (de) 2004-05-12
WO2003008571A9 (es) 2004-04-15
MXPA04000486A (es) 2005-03-07
DK1418180T3 (da) 2007-05-07
WO2003008571A3 (es) 2004-03-04
CN100378123C (zh) 2008-04-02
DE60217129T2 (de) 2007-10-31
CA2453300A1 (en) 2003-01-30
US7947281B2 (en) 2011-05-24
BR0211178A (pt) 2004-08-10
WO2003008571A2 (es) 2003-01-30
JP4417712B2 (ja) 2010-02-17
KR20040030056A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
WO2007149715A3 (en) Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
DE60234375D1 (de) VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
ATE349466T1 (de) Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
WO2002095023A3 (en) Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
DK1536006T3 (da) Cancerantigener og anvendelse deraf
Xue et al. Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions
DE602004018975D1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
JP2011120598A (ja) Hla結合性ペプチド、それをコードするdna断片および組み換えベクター
ZA200602107B (en) Piroplasmid vaccine
DE60234475D1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
BR9508645A (pt) Vacina da peritonite infecciosa felina
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
WO2002038769A3 (de) Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
EP1281758A3 (de) Vier menschliche Zinc-Finger Proteine: MDZ3, MDZ4, MDZ7 und MDZ12
DE69533167D1 (de) Impfstoffe gegen den hepatitis b und c virus
WO2005001096A8 (fr) Vaccins contre le sras

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1418180

Country of ref document: EP

REN Ceased due to non-payment of the annual fee